156 related articles for article (PubMed ID: 1456797)
1. Nursing guidelines for muromonab-CD3 (OKT3).
Duffy MM; Nestor A
ANNA J; 1992 Oct; 19(5):493-5. PubMed ID: 1456797
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
3. OKT 3: nursing considerations for use in acute renal transplant rejection.
Trusler LA
ANNA J; 1990 Aug; 17(4):299-303. PubMed ID: 2118750
[TBL] [Abstract][Full Text] [Related]
4. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
5. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
Pomer S; Waldherr R; Möhring K; Kempter F; Wiesel M; Weimer R
Transplant Proc; 1992 Oct; 24(5):1732-3. PubMed ID: 1412815
[No Abstract] [Full Text] [Related]
6. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
[No Abstract] [Full Text] [Related]
7. Low-dose OKT3 for cadaveric renal transplantation.
Schweizer RT; Roper L; Hull D; Bartus SA
Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
[No Abstract] [Full Text] [Related]
8. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
[No Abstract] [Full Text] [Related]
9. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
10. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
Wilde MI; Goa KL
Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
[TBL] [Abstract][Full Text] [Related]
11. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE
Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246
[No Abstract] [Full Text] [Related]
12. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
13. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
Carrier M; Jenicek M; Pelletier LC
Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
[No Abstract] [Full Text] [Related]
14. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
[No Abstract] [Full Text] [Related]
15. [Nursing care of acute rejection after kidney transplantation treated with OKT3].
Zhu BL; Li LP
Zhonghua Hu Li Za Zhi; 1993 Mar; 28(3):152-4. PubMed ID: 8334726
[No Abstract] [Full Text] [Related]
16. Evidence for granulocyte activation by OKT3.
Schmaldienst S; Böhmig G; Pohanka E; Kovarik J; Zlabinger GJ
Transplant Proc; 1992 Dec; 24(6):2600-1. PubMed ID: 1465878
[No Abstract] [Full Text] [Related]
17. Results of a prospective, randomized double-blind study comparing standard vs low-dose OKT3 induction therapy.
Alloway R; Kotb M; Hathaway DK; Gaber LW; Vera SR; Gaber AO
Transplant Proc; 1993 Feb; 25(1 Pt 1):550-2. PubMed ID: 8438410
[No Abstract] [Full Text] [Related]
18. [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].
Müller T; Keuchel M; Schindler S; Steinmetz A; Feiber H; Lange H
Helv Chir Acta; 1991 Sep; 58(3):271-5. PubMed ID: 1769844
[TBL] [Abstract][Full Text] [Related]
19. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
20. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
[Next] [New Search]
